Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid"). 1984

I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler

A 22-yr-old diabetic female is described who developed insulin resistance due to subcutaneous (and intramuscular) "malabsorption" of insulin resulting in recurrent ketoacidosis and sepsis. Intravenous insulin sensitivity was maintained. Diverse attempts to prevent metabolic decompensation by "external" methods failed. The insulin resistance was treated successfully by a totally implantable insulin infusion device ("INFUSAID") with no episodes of ketoacidosis in the 6 months following implantation. With this constant rate insulin infusion pump, and no supplementation of insulin dose by other means, the plasma glucose control is excellent and serum lipid and glycosylated haemoglobin (HbA1) levels have returned to normal.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007332 Insulin Infusion Systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. Pancreas, Artificial Endocrine,Programmable Implantable Insulin Pump,beta Cell, Artificial,Implantable Programmable Insulin Pump,Insulin Pump, Programmable Implantable,Pump, Programmable Implantable Insulin,Artificial Endocrine Pancreas,Artificial beta Cell,Artificial beta Cells,Cell, Artificial beta,Cells, Artificial beta,Endocrine Pancreas, Artificial,Infusion System, Insulin,Infusion Systems, Insulin,Insulin Infusion System,System, Insulin Infusion,Systems, Insulin Infusion,beta Cells, Artificial
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016883 Diabetic Ketoacidosis A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA. Acidosis, Diabetic,DKA Diabetic Ketoacidosis,Diabetic Acidosis,Diabetic Ketosis,Ketoacidosis, Diabetic,Ketosis, Diabetic,Acidoses, Diabetic,DKA Diabetic Ketoacidoses,Diabetic Acidoses,Diabetic Ketoacidoses,Diabetic Ketoacidosis, DKA,Diabetic Ketoses,Ketoacidoses, Diabetic,Ketoacidosis, DKA Diabetic,Ketoses, Diabetic

Related Publications

I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
June 1981, Lancet (London, England),
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
October 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
March 1984, British medical journal (Clinical research ed.),
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
December 1983, British medical journal (Clinical research ed.),
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
July 1979, Diabetes,
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
January 1983, Transactions - American Society for Artificial Internal Organs,
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
May 1982, Diabetes,
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
January 1981, Diabetes care,
I W Campbell, and H Kritz, and C Najemnik, and G Hagmueller, and K Irsigler
January 1981, Neurosurgery,
Copied contents to your clipboard!